CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade CNS Pharmaceuticals, Inc. - CNSP CFD

0.1011
6.22%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0016
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.21)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.1078
Open 0.1066
1-Year Change -84.89%
Day's Range 0.1006 - 0.1066
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2025 0.1011 -0.0055 -5.16% 0.1066 0.1066 0.1005
Jan 16, 2025 0.1078 -0.0007 -0.65% 0.1085 0.1108 0.1056
Jan 15, 2025 0.1085 0.0009 0.84% 0.1076 0.1131 0.1044
Jan 14, 2025 0.1067 -0.0039 -3.53% 0.1106 0.1106 0.1016
Jan 13, 2025 0.1165 -0.0021 -1.77% 0.1186 0.1222 0.1068
Jan 10, 2025 0.1165 0.0069 6.30% 0.1096 0.1216 0.1040
Jan 8, 2025 0.1151 0.0065 5.99% 0.1086 0.1224 0.1026
Jan 7, 2025 0.1095 -0.0011 -0.99% 0.1106 0.1147 0.1047
Jan 6, 2025 0.1184 -0.0262 -18.12% 0.1446 0.1597 0.1111
Jan 3, 2025 0.1207 0.0047 4.05% 0.1160 0.1316 0.1136
Jan 2, 2025 0.1149 -0.0067 -5.51% 0.1216 0.1226 0.1116
Dec 31, 2024 0.1195 0.0009 0.76% 0.1186 0.1208 0.1107
Dec 30, 2024 0.1095 -0.0011 -0.99% 0.1106 0.1135 0.1046
Dec 27, 2024 0.1108 -0.0039 -3.40% 0.1147 0.1168 0.1016
Dec 26, 2024 0.1125 0.0039 3.59% 0.1086 0.1267 0.1075
Dec 24, 2024 0.1075 0.0004 0.37% 0.1071 0.1083 0.1042
Dec 23, 2024 0.1067 -0.0030 -2.73% 0.1097 0.1107 0.1028
Dec 20, 2024 0.1087 0.0046 4.42% 0.1041 0.1172 0.1041
Dec 19, 2024 0.1096 0.0000 0.00% 0.1096 0.1131 0.1016
Dec 18, 2024 0.1099 -0.0077 -6.55% 0.1176 0.1176 0.1026

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

CNS Pharmaceuticals, Inc. Company profile

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.

Industry: Biotechnology & Medical Research (NEC)

2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US

People also watch

BTC/USD

104,252.25 Price
+4.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

US100

21,441.70 Price
+1.820% 1D Chg, %
Long position overnight fee -0.0233%
Short position overnight fee 0.0011%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

3,435.27 Price
+3.830% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading